Calistoga Tells Del. Justices Gilead Owes $50M Drug Bonus
Delaware's chancellor erred by considering outside evidence rather than strict contract terms in a $50 million dispute between merger partners over a cancer drug bonus payment, attorneys for Calistoga Pharmaceuticals Inc.'s...To view the full article, register now.
Already a subscriber? Click here to view full article